A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 31, Issue 10, 2001, Pages 482-487

  Akiyama, Yoshiko ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a   Sawada, Masahiro ^a   Inoue, Akira ^a   Kusaba, Hitoshi ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Kunitoh, Hideo ^a   Kodama, Tetsuro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPONATREMIA; JAPAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY;

EID: 0034753937     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye111     Document Type: Article

References (30)

1. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis
2. Chemotherapy versus supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials
4. Taxol: The first of the taxanes, an important new class of antitumor agents
5. Promotion of microtubule assembly in vitro by taxol
6. Taxol stabiles microtubules in mouse fibroblast cells
7. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results
8. Taxol: A novel investigational antimicrotubule agent
9. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
10. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
11. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre
12. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group (SWOG) Trial
13. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
14. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
15. Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities
16. Phase II study of 3-h infusion of paclitaxel in previously untreated non-small cell lung cancer
17. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
18. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
19. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
20. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
21. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
22. Paclitaxel 3-h infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials
23. Clinical experiences with carboplatin (paraplatin) in lung cancer
24. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
25. Sequences of taxol and cisplatin: A phase I and pharmacologic study
26. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
27. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
28. Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins
29. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy
30. Clinical pharmacology of carboplatin administered in combination with paclitaxel